Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Bamlanivimab

- PMLiVE

Eli Lilly, Innovent showcase Tyvyt data in first-line NSCLC

Detailed phase 3 results presented at the virtual World Conference on Lung Cancer

- PMLiVE

Eli Lilly begins COVID-19 prevention trial in nursing homes

Trial will investigate monoclonal antibody in up to 2,400 participants

- PMLiVE

Boehringer/Lilly’s Jardiance hits the mark in pivotal heart failure trial

Drug reduced risk of death/hospitalisation in patients with and without diabetes

- PMLiVE

FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes

Formally rejects extended use of SGLT2 inhibitor

- PMLiVE

Lilly halts most clinical trials as coronavirus disruption continues

Will continue ongoing trials for patients who are already enrolled

- PMLiVE

Lilly partners with Indiana State Health Department for coronavirus testing

Experts maintain that testing can curb the outbreak

- PMLiVE

Lilly and AbCellera partner on antibody therapies for COVID-19

Latest companies to join the fight against the novel coronavirus

- PMLiVE

Lilly joins new Medicare scheme to reduce insulin prices

New model will cover seniors enrolled in Medicare Part D

- PMLiVE

Modest meeting sees only two drugs recommended by CHMP

Lilly’s migraine med Emgality receives negative opinion for label extension

- PMLiVE

Lilly’s Cyramza narrowly clears FDA adcomm vote for first-line NSCLC

Advisory committee voted 6-5 in favour of drug

- PMLiVE

Lilly’s Trulicity scores CV reduction indication in the US

Approved for risk reduction in primary and secondary populations

- PMLiVE

Double blow to amyloid drug hopes as Roche, Lilly trial fails

The two investigational candidates were unable to show benefit

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links